Interferon News and Research

RSS

IRF7 reshapes the behavior of vascular smooth muscle cells during atherosclerosis

Atherosclerosis underlies most heart attacks and strokes and is now recognized as a chronic inflammatory disease rather than a simple disorder of cholesterol deposition.

9 Feb 2026

Dynamic viral markers predict treatment response in hepatitis B

The rate of functional cure (HBsAg loss) remains unsatisfactory following pegylated interferon (PEG-IFN) treatment in chronic hepatitis B. To optimize PEG-IFN administration, this study aimed to evaluate virological markers to predict functional cure and/or hepatitis B e antigen (HBeAg) loss.

30 Jan 2026

Purdue researchers discover new therapeutic target for triple-negative breast cancer

A Purdue University team led by Kyle Cottrell has discovered a new therapeutic target for triple-negative breast cancer.

27 Jan 2026

Study identifies a powerful strategy to overcome drug resistance in breast cancer

A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Communications, identifies a powerful strategy to overcome drug resistance in breast cancer by simultaneously targeting two key cell-cycle regulators, CDK2 and CDK4/6.

22 Jan 2026

Interferon response key to fighting rhinovirus infections in nasal passages

When a rhinovirus, the most frequent cause of the common cold, infects the lining of our nasal passages, our cells work together to fight the virus by triggering an arsenal of antiviral defenses.

19 Jan 2026

BATF2: A novel tumor suppressor silenced by glutamine in head and neck cancer

A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune response in five preclinical models of head and neck cancer, according to researchers from The University of Texas MD Anderson Cancer Center.

7 Jan 2026

A single immune protein may help explain why kidney and heart disease often develop together

This review synthesizes clinical, genetic, and mechanistic evidence showing that suPAR and related uPAR fragments are strongly associated with kidney, cardiovascular, and metabolic disease risk. It highlights suPAR as a stable biomarker of innate immune activation with potential pathogenic roles, while underscoring major gaps in assay standardization and therapeutic validation.

6 Jan 2026

COVID-19 immunity stays specific and barely boosts protection against common cold coronaviruses

This study shows that SARS-CoV-2 infection and vaccination generate strong, highly specific spike-binding immune responses with only modest effects on immunity to endemic common cold coronaviruses. Pre-existing coronavirus immunity patterns remain largely intact, indicating that SARS-CoV-2 has integrated into the human viral landscape without broadly reshaping cross-reactive protection.

5 Jan 2026

Study uncovers how aggressive breast cancer cells escape immune defenses

With a new study in the journal Science Bulletin, researchers at Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University have discovered a new way that aggressive breast cancer cells escape the immune defenses.

1 Jan 2026

Researchers explore why Alzheimer's affects men and women differently

More than seven million Americans have Alzheimer's disease, and two-thirds of them are women, according to the Alzheimer's Association. The O'Banion Lab at the Del Monte Institute for Neuroscience at the University of Rochester has long been studying this disease and is looking more closely at the differences between male and female brains.

30 Dec 2025

Remodeling the tumor microenvironment to unlock CAR-T cell potential

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor microenvironment (TME).

22 Dec 2025

Research reveals how the gut microbiome supports successful pregnancy

Gut microbes may play a key role in training a mother's immune system to adapt to the developing fetus during pregnancy, according to a preclinical study by Weill Cornell Medicine investigators.

17 Dec 2025

SARS-CoV-2 manipulates host cell's RNA to weaken the immune response

Researchers at the Federal University of São Paulo (UNIFESP) in Brazil have discovered that SARS-CoV-2, the virus that causes COVID-19, uses a sophisticated tactic to evade the human body's defense system.

17 Dec 2025

Researchers develop nasal antiviral platform using AI technology to block flu and COVID-19

Respiratory viruses that have diverse strains and mutate rapidly, such as influenza and COVID-19, are difficult to block perfectly with vaccines alone.

15 Dec 2025

New findings show why the human intestine uniquely presents gluten to T cells

Human intestinal M cells function as dendritic cell-like antigen-presenting cells, displaying constitutive MHC-II activity and specialized machinery for processing gluten. Their ability to deamidate and present gliadin peptides positions them as key initiators of immune responses relevant to coeliac disease.

11 Dec 2025

Study reveals how Ebola and Marburg viruses damage the human gut

Ebola (EBOV) and Marburg virus (MARV) are highly lethal viruses that cause severe disease in infected patients by extensively damaging the body.

11 Dec 2025

Lubiprostone shows signs of slowing kidney function decline in chronic kidney disease

In adults with stage IIIb–IV chronic kidney disease, the constipation drug lubiprostone did not reduce gut-derived uremic toxins but preserved creatinine-based kidney function over 24 weeks. The benefit was linked to microbiome remodeling, increased polyamine production, and improved mitochondrial function rather than toxin lowering.

8 Dec 2025

Targeted approach of immunotherapy improves sepsis outcomes

Immunotherapy for sepsis is effective when doctors tailor the treatment precisely to the patient's immune system condition.

8 Dec 2025

Novel antibody suppresses primary tumor growth and spread of triple-negative breast cancer

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other breast cancers treatable with targeted therapies.

5 Dec 2025

Study uncovers strategy to sensitize estrogen receptor–positive breast tumors to immunotherapy

A study led by researchers at the Hospital del Mar Research Institute advances one of the most significant milestones in breast cancer treatment, making immunotherapy effective against the most common tumor type, estrogen receptor-positive or luminal breast cancer.

4 Dec 2025